Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Discontinuing Antiviral Treatment in HBeAg-Negative Chronic Hepatitis B
NCT04782375Phase 4Completed
- Sponsor
- Asan Medical Center
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in Chronic Hepatitis B (CHB), sponsored by Asan Medical Center. Primary endpoint: Virological relapse at 48 weeks. Started Sep 2021; status: completed.
02
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04782375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782375.